Armata Pharmaceuticals, Inc. filed a Form 8-K with the SEC on September 23, 2026, disclosing receipt of $3.7 million in additional non-dilutive funding from the U.S. Department of War to support Phase 3 development of its phage product candidate AP-SA02.

Key Highlights

  • $3.7 million received: Armata Pharmaceuticals disclosed receipt of $3.7 million in additional non-dilutive funding.
  • Funding source: The funds were provided by the U.S. Department of War (DoW).
  • Program supported: The funding supports activities associated with the Phase 3 development program for AP-SA02.
  • Product description: AP-SA02 is described as an intravenously administered Staphylococcus aureus multi-phage product candidate for the adjunct treatment of complicated bacteremia caused by methicillin-sensitive or methicillin-resistant S. aureus.
  • Announcement date: The press release was issued on September 23, 2026, and is attached as Exhibit 99.1 to the filing.

Armata Discloses Additional Government Funding for AP-SA02 Phase 3 Program

According to the filing, Armata Pharmaceuticals, Inc. (NYSE American:ARMP) issued a press release on September 23, 2026, announcing that it had received $3.7 million in additional non-dilutive funding from the U.S. Department of War. The company disclosed that this funding is intended to support activities associated with its Phase 3 development program for AP-SA02.

The filing describes AP-SA02 as the company's intravenously administered Staphylococcus aureus multi-phage product candidate. According to the filing, AP-SA02 is being developed for the adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin-resistant S. aureus. The company characterized the funding as non-dilutive, meaning it does not involve the issuance of new equity to receive the funds.

The 8-K was signed by David House, Chief Financial Officer of Armata Pharmaceuticals, Inc., on September 23, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 and incorporated by reference into the Current Report.

What Was Disclosed

Armata Pharmaceuticals filed an 8-K on September 23, 2026, reporting receipt of $3.7 million in additional non-dilutive funding from the U.S. Department of War to support the Phase 3 development program for its AP-SA02 phage product candidate targeting S. aureus bacteremia.